Hainan Huluwa Pharmaceutical Group Management
Management criteria checks 2/4
Hainan Huluwa Pharmaceutical Group's CEO is Jinping Liu, appointed in Feb 2016, has a tenure of 8.83 years. directly owns 41.76% of the company’s shares, worth CN¥2.61B. The average tenure of the management team and the board of directors is 8.8 years and 6.1 years respectively.
Key information
Jinping Liu
Chief executive officer
CN¥1.4m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 8.8yrs |
| CEO ownership | 41.8% |
| Management average tenure | 8.8yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
CEO
Jinping Liu (54 yo)
8.8yrs
Tenure
CN¥1,406,000
Compensation
Ms. Liu Jinping serves as General Manager of Hainan Huluwa Pharmaceutical Group Co., Ltd. since February 26, 2016 and serves as its Chairman of the Board since December 2007 and serves as its Director.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | 8.8yrs | CN¥1.41m | 41.76% CN¥ 2.6b | |
| Secretary | 3.5yrs | CN¥517.80k | no data | |
| Deputy General Manager | 8.8yrs | CN¥435.70k | no data | |
| Accounting Supervisor | no data | no data | no data |
8.8yrs
Average Tenure
54yo
Average Age
Experienced Management: 605199's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | 17yrs | CN¥1.41m | 41.76% CN¥ 2.6b | |
| Independent Director | 6.1yrs | CN¥100.00k | no data | |
| Supervisor | 6.1yrs | no data | no data | |
| Chairman of the Supervisory Board | no data | no data | no data |
6.1yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 605199's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 09:50 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hainan Huluwa Pharmaceutical Group Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|